From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Cyclophosphamide is a chemotherapy and immunosuppressant drug. It is often used as an adjuvant drug with other chemotherapy medications especially for leukemia and lymphomas. (These cancers include Hodgkin’s and non-Hodgkin's lymphoma, Burkitt’s lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), t-cell lymphoma (mycosis fungoides), multiple myeloma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, Ewing's sarcoma; breast, testicular, endometrial, ovarian, and lung cancers, and in conditioning regimens for bone marrow transplantation.)[1]

Theory[edit | edit source]

Evidence[edit | edit source]

Norwegian Study - Cyclo/ME[edit | edit source]

There is no evidence for the use of the drug to treat ME/CFS.

A Norwegian group, led by the researchers, Dr. Øystein Fluge and Professor Olav Mella, who are studying Rituximab use in ME/CFS, are running a clinical trial, called CycloME. The trial will test the effects of cyclophosphamide on ME/CFS patients that have been non-responders to Rituximab.[2][3]

Risks & safety[edit | edit source]

Costs & availability[edit | edit source]

At present, only one clinical trial site, CycloME, is testing cyclophosphamide for use in ME/CFS.</ref>[4]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

Myalgic encephalomyelitis or M.E. has different diagnostic criteria to chronic fatigue syndrome; neurological symptoms are required but fatigue is an optional symptom.<ref name="ICP2011primer">{{Citation

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.